We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Treatment with diabetes drug canagliflozin lowers the PromarkerD risk score for developing diabetic kidney disease in patients with type 2 diabetes, latest research suggests.
Proteomics International Laboratories Ltd announces testing for diabetic kidney disease with the PromarkerD prognostic blood test could save US payers almost USD400 billion over 10 years, research suggests.